ESR1 and cancer: Although this suggests that the epigenetic silencing of ESR1 via DNA methylation is reversible, and demethylation can potentially restore ERα expression, a clinical use, e.g., aiming at re-sensitizing cancers to hormone therapies, is not possible, since demethylating drugs are totally unspecific and thus could lead to an increased expression of pathobiologically active genes like oncogenes.